Loading…
Loading…
WINT does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for WINT and 80,000+ other tickers.
See exactly how WINT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for WINT and 80,000+ other tickers.
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for…
Company plans reverse merger with Windtree Therapeutics as it expands its AI-powered commercial lending marketplace SCOTTSDALE, Ariz., March 17, 2026 /PRNewswire/ -- CommLoan, a commercial real estate lending technology company operating the first true AI-powered commercial mortgage lending marketplace, announced today that it has obtained the final approvals needed to operate and do business in all 50 states, without restriction.
Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree to acquire Titan Environmental Services, Inc. The executed agreement releases the parties from their reciprocal surviving obligations WARRINGTON, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that it has signed a letter of intent with TESI (OTC: TESI), an environmental services company, and Windtree will receive $7.5 million in cash and TESI securities.
Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree to acquire Titan Environmental Services, Inc. The executed agreement releases the parties from their reciprocal surviving obligations WARRINGTON, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that it has signed a letter of intent with TESI (OTC: TESI), an environmental services company, and Windtree will receive $7.5 million in cash and TESI securities.
Windtree Therapeutics, Inc. (NASDAQ: WINT - Get Free Report) was the recipient of a large decrease in short interest in October. As of October 15th, there was short interest totaling 218,900 shares, a decrease of 26.2% from the September 30th total of 296,700 shares. Currently, 6.0% of the company's shares are sold short. Based on an
Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C